Publication date: Jul 09, 2025
Randomized to receive either 500 mg of nicotinamide riboside (Niagen) twice daily or placebo for 52 weeks, participants had follow-up assessments at five time points in a one-year period. The agreement secures exclusive rights to a body of proprietary intellectual property, know-how, and data. NOPARK is a randomized, double-blind, placebo-controlled phase III clinical trial featuring 400 individuals with early-stage PD across 12 sites in Norway. The study was recently completed in June 2025 and is expected to be published by the end of 2025. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. We are fully committed to advancing knowledge and developing treatments that can truly benefit patients with PD and other neurodegenerative disorders. Theres a better way to age. Niagen Biosciences robust patent portfolio protects NR and other NAD+ precursors.
| Concepts | Keywords |
|---|---|
| 1282niagenir | Agreement |
| Biotech | Bioscience |
| June | Clinical |
| Norwegian | Haukeland |
| Therapy | License |
| Looking | |
| Nad+ | |
| Niagen | |
| Nicotinamide | |
| Nopark | |
| Phase | |
| Potential | |
| Published | |
| Regulatory | |
| Statements |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Parkinson’s Disease |
| drug | DRUGBANK | Nadide |
| drug | DRUGBANK | Nonoxynol-9 |
| drug | DRUGBANK | Gold |
| disease | MESH | neurodegenerative disorders |
| pathway | REACTOME | Metabolism |
| pathway | REACTOME | Neurodegenerative Diseases |
| drug | DRUGBANK | Coenzyme M |
| disease | MESH | lifestyle |
| drug | DRUGBANK | Tropicamide |
| pathway | REACTOME | Release |
| drug | DRUGBANK | Spinosad |